Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood (2017) 129 (11): 1469–1479.

https://doi.org/10.1182/blood-2016-06-719294

Published: 2017

Includes: Supplemental data

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways

Sarah E. M. Herman, PhD, Delong Liu, PhD, Dan A. Landau, MD PhD, Clare Sun, MD, Mohammed Farooqui, Catherine J Wu, MD, Adrian Wiestner, MDPhD

Blood (2016) 128 (22): 189.

https://doi.org/10.1182/blood.V128.22.189.189

Published: 2016

Journal Articles

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Inhye E Ahn, MD, Xin Tian, Susan Soto, Janet Valdez, Jennifer Lotter, Mohammed Farooqui, Adrian Wiestner, MD PhD

Blood (2016) 128 (22): 187.

https://doi.org/10.1182/blood.V128.22.187.187

Published: 2016

Journal Articles

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Inhye E. Ahn, Theresa Jerussi, Mohammed Farooqui, Xin Tian, Adrian Wiestner, Juan Gea-Banacloche

Blood (2016) 128 (15): 1940–1943.

https://doi.org/10.1182/blood-2016-06-722991

Published: 2016

Journal Articles

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

Layla M Saleh, MD, Weixin Wang, PhD, Sarah E. M. Herman, PhD, Mohammed Farooqui, DO, Clare Sun, MD, Emily Barber, B.S., Meghan Corrigan-Cummins, B.S., Nakhle Saba, MD, Hasan Awad, MD, PhD, Adrian Wiestner, MD PhD, Katherine R. Calvo, MD, PhD

Blood (2015) 126 (23): 487.

https://doi.org/10.1182/blood.V126.23.487.487

Published: 2015

Journal Articles

High Sensitivity Testing Shows Multiclonal Mutations in Patients with CLL Treated with BTK Inhibitor and Lack of Mutations in Ibrutinib-Naive Patients

Adam Albitar, Wanlong Ma, BS, Ivan De Dios, Jeffrey Estrella, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD, Maher Albitar

Blood (2015) 126 (23): 716.

https://doi.org/10.1182/blood.V126.23.716.716

Published: 2015

Journal Articles

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Inhye Ahn, MD, Mohammed Farooqui, DO, Yuh Shan Lee, Gerald Marti, Susan Soto, RN, Xin Tian, PhD, Maryalice Stetler-Stevenson, Constance M. Yuan, MD PhD, Irina Maric, MD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 1750.

https://doi.org/10.1182/blood.V126.23.1750.1750

Published: 2015

Journal Articles

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Amanda Bray, RN, Xin Tian, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2933.

https://doi.org/10.1182/blood.V126.23.2933.2933

Published: 2015

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 1936.

https://doi.org/10.1182/blood.V124.21.1936.1936

Published: 2014

Journal Articles

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer A. Gyamfi, Stefania Pittaluga, Stella Chang, Betty Chang, Mohammed Farooqui, Adrian Wiestner

Blood (2014) 123 (21): 3286–3295.

https://doi.org/10.1182/blood-2014-02-548610

Published: 2014

Includes: Supplemental data

Journal Articles

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Georg Aue, MD, Mohammed Farooqui, DO, Jade Jones, Janet Valdez, PA, Sabrina E. Martyr, MD, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 4182.

https://doi.org/10.1182/blood.V122.21.4182.4182

Published: 2013

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

Journal Articles

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Carsten U Niemann, MD, PhD, Angelique Biancotto, PhD, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, J. Philip McCoy, Jr., Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 2856.

https://doi.org/10.1182/blood.V122.21.2856.2856

Published: 2013

Journal Articles

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Sarah E. M. Herman, PhD, Jade Jones, Rashida Z. Mustafa, BS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 604.

https://doi.org/10.1182/blood.V122.21.604.604

Published: 2013

Journal Articles

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Mohammed Farooqui, DO, Georg Aue, MD, Janet Valdez, PA, Sabrina Martyr, MD, Jade Jones, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Diane C Arthur, M.D., Francine Thomas, B.S., Xin Tian, PhD, Delong Liu, PhD, Irina Maric, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 673.

https://doi.org/10.1182/blood.V122.21.673.673

Published: 2013

Journal Articles

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Rashida Z Mustafa, BS, Sarah E. M. Herman, PhD, Jade Jones, Jennifer Gyamfi, MS, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 674.

https://doi.org/10.1182/blood.V122.21.674.674

Published: 2013

Journal Articles

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Mark Roschewski, MD, Mohammed Farooqui, DO, Georg Aue, MD, Clifton C. Mo, MD, Janet Valdez, PA, Susan Soto, RN, Patricia Perez-Galan, PhD, Francois Wilhelm, MD, PhD., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1803.

https://doi.org/10.1182/blood.V120.21.1803.1803

Published: 2012

NARROW

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia

High Sensitivity Testing Shows Multiclonal Mutations in Patients with CLL Treated with BTK Inhibitor and Lack of Mutations in Ibrutinib-Naive Patients

Risk-Adapted Induction and Maintenance with Ofatumumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

In Vivo Ibrutinib Abrogates BCR-Dependent Adhesion in Tumor Cells of Patients with Chronic Lymphocytic Leukemia

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only